Altimmune (ALT) Aandelenoverzicht

Altimmune, Inc., een biofarmaceutisch bedrijf in een laat klinisch stadium, richt zich op de ontwikkeling van nieuwe therapieën voor ernstige leverziekten. Meer informatie

ALT fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 65.83% per jaar groeien

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $41K )

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Community Fair Values

Altimmune, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Altimmune
Historische aandelenkoersen
Huidige aandelenkoers	US$3.04
52 Week Hoogtepunt	US$7.73
52 Week Laag	US$2.56
Bèta	0.17
1 maand verandering	-10.06%
3 maanden verandering	-37.58%
1 Jaar Verandering	-47.59%
3 jaar verandering	-42.96%
5 jaar verandering	-76.14%
Verandering sinds IPO	-98.72%

Recent nieuws en updates

Seeking Alpha • Apr 09

Altimmune: Considering If A Repeat Of The 2025 Run-Up Is On Tap

Summary Altimmune has announced it expects to produce topline data from its phase 2 RECLAIM study of pemvidutide in alcohol use disorder. ALT is planning to start a large phase 3 of pemvidutide in MASH in 2026, although it hasn't provided a more specific timeline than that. ALT's $340M cash runway extends into 2028, but further ATM usage or offerings could suppress share price rallies and introduce dilution risk. ALT's RECLAIM study is not without a chance of success, other incretins have shown promise in alcohol use disorder previously. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Apr 09

Altimmune: Considering If A Repeat Of The 2025 Run-Up Is On Tap

Seeking Alpha • Mar 17

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine

Summary Altimmune, Inc.'s top-line data from the phase 2b IMPACT study using pemvidutide for the treatment of patients with MASH expected in Q2 of 2025. The global non-alcoholic steatohepatitis [NASH] market could reach $39.3 billion by 2031. Company received IND clearance from the FDA to advance two mid-stage studies using pemvidutide to target patients with AUD and ALD; First phase 2 study to start in mid-2025. Pemvidutide is also being developed for patients with obesity; ALT received clearance from the FDA to run four phase 3 studies for possible eventual marketing approval in targeting these patients. Read the full article on Seeking Alpha

Seeking Alpha • Feb 28

Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2

Summary Altimmune's pemvidutide shows promise in treating MASH with obesity, potentially positioning it as a first-in-class drug targeting both liver health and weight loss. Despite past volatility, ALT stock has stabilized, with recent data showing significant weight loss at higher doses, sparking renewed investor interest. Altimmune's Q4 2024 earnings reveal a net loss of $23.2m, with $131.9m in cash, highlighting the company's ongoing financial challenges and reliance on future clinical success. Investors should watch for the Phase 2b IMPACT study results in Q2 2025, which could significantly impact Altimmune's stock and future prospects in the MASH market. Read the full article on Seeking Alpha

Seeking Alpha • Feb 18

Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH

Summary Altimmune is a single-molecule company currently trading at a $0.5 billion market cap with a favorable risk-reward profile. The company's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH (metabolic dysfunction-associated steatohepatitis). Pemvidutide has successfully completed a Phase 1 trial for a related liver disease but has yet to demonstrate efficacy in the target indication of MASH. Direct peers such as Akero Therapeutics and Madrigal have more advanced clinical trials and are valued at $2 billion and $7 billion, respectively, implying significant upside potential for ALT stock. Comparable catalysts for MASH show that Altimmune, with positive Phase 2 data, could experience a market cap expansion of $475 million, equating to an almost 80% upside. Read the full article on Seeking Alpha

Analyse-artikel • Jan 15

Is Altimmune (NASDAQ:ALT) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Dec 30

Altimmune Could Find A Partner For Its Phase 3 Exercise

Summary ALT's end-of-phase 2 meeting with the FDA provided a clear clinical plan for pemvidutide, but the phase 3 program will require 5,000 patients. ALT's $139M in cash is enough to stay afloat for a while at the current rate, but not to fund phase 3, the company needs a partner or a buyout. If ALT can't find a partner or be acquired, then a hefty fund raise awaits investors, which could hit the stock. Despite competition, the potential for a partnership or buyout remains strong, as Big Pharma continues to show interest in weight loss drugs, and ALT seems cheap compared to its peers. Read the full article on Seeking Alpha

Seeking Alpha • Dec 16

Altimmune 2025: Redefining Obesity And MASH Treatment

Summary Altimmune is entering both obesity and MASH markets with a powerful GLP-1/Glucagon dual-agonist drug called Pemvidutide, offering fat-specific weight loss and muscle preservation with a strong safety profile. Altimmune is redefining success in both obesity and MASH to position Pemvidutide in "blue ocean" categories not addressed by incumbents and catered to the unique strengths of Glucagon in Pemvidutide. Valuation of on-label and off-label use of Pemvidutide across all indications and comorbidities show that Altimmune is significantly undervalued at current share prices, factoring in all risks. Read the full article on Seeking Alpha

Seeking Alpha • Nov 13

Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health

Summary Altimmune, Inc.’s Pemvidutide shows promise as a dual-action treatment for obesity and MASLD/MASH, targeting weight loss, liver health, and cardiovascular support. Their Phase 2 MOMENTUM trial for obesity demonstrated significant weight loss and lean mass preservation, with up to 15.6% weight reduction at the highest dose. Altimmune’s cash runway is estimated to support operations into 1H2026, aligning with expected milestones and anticipated Phase 3 trials. The company plans to expand Pemvidutide’s applications with a new IND for additional indications by year-end, enhancing its market potential. Thus, I am upgrading ALT stock to a “Strong Buy” due to the promising progress of its lead drug candidate, sufficient runway, and several future catalysts. Read the full article on Seeking Alpha

Seeking Alpha • Oct 28

Regulatory And Clinical Catalysts Ahead For Altimmune

Summary ALT is developing pemvidutide for obesity and liver diseases, with recent MOMENTUM sub-study results showing favorable body composition results. A readout from the Phase 2b trial of pemvidutide in MASH is delayed to Q2'25, although the trial has completed enrollment, making further delays unlikely. ALT has $164.9M in cash but may need additional funding for phase 3 trials; a partnership for phase 3 development in obesity remains a possibility. Read the full article on Seeking Alpha

Seeking Alpha • Oct 02

Consider Buying Potential Takeover Target Altimmune

Summary Altimmune, Inc.'s weight loss drug, pemvidutide, shows significant superiority in lean mass retention and liver fat reduction, making it a potential takeover target. High short interest in Altimmune stock could trigger a short-covering rally if reports of takeover talks emerge. Pemvidutide's superior lean mass retention could enable it to capture market share from Novo Nordisk's Wegovy and Eli Lilly's tirzepatide. Read the full article on Seeking Alpha

Seeking Alpha • Sep 21

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

Summary Pemvidutide shows strong potential in obesity and MASH, preserving lean mass while reducing VAT, which could make it a market leader among GLP-1s. Recent Phase II data reveals pemvidutide's lean loss ratio of 21.9%, comparable to diet and exercise, and significant VAT reduction, enhancing its appeal. Despite competition and risks, I am bullish on ALT, upgrading my conviction rating and planning to add to my position below $8.20 per share. Pemvidutide's dual indications for obesity and MASH, along with potential cardiovascular benefits, could drive Altimmune to blockbuster status and significant revenue growth. Read the full article on Seeking Alpha

Analyse-artikel • Sep 12

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, Altimmune ( NASDAQ:ALT...

Seeking Alpha • Aug 27

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Summary Weight loss drugs like Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide dominate the market, with Novo Nordisk leading in sales and Amgen developing a novel competitor. Altimmune’s pemvidutide shows promising weight loss and lean mass preservation but faces high discontinuation rates and lacks sugar control, unlike rivals. Financially, Altimmune has a cash runway of five to six quarters, necessitating a likely dilution before their phase 3 trial's completion. Despite promising data, Altimmune's pemvidutide faces tough competition from established players, making it a risky investment without more differentiating metrics. Read the full article on Seeking Alpha

Seeking Alpha • Jun 24

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Summary Altimmune, Inc. shares surged nearly 30% after positive Phase 2 clinical study results for pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity and MASH. Pemvidutide may compete with Novo Nordisk's semaglutide and Eli Lilly's tirzepatide, which have demonstrated miraculous weight loss improvements, and will likely dominate a ~$130bn market. Altimmune's latest data shows significant weight loss and lean muscle preservation - the latter may be most significant. If pemvidutide can show it removes less lean muscle fat than competing GLP-1 agonist drugs, it may be on a fast track to approval and a double-digit billion dollar revenue opportunity. It is not quite so simple as it sounds, however - other candidates are yet to fully show their hands, and Altimmune is a minnow compared to the large pharmas crowding this space. Nevertheless, it is an interesting development. Read the full article on Seeking Alpha

Seeking Alpha • May 27

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

Summary Altimmune is developing an anti-obesity drug, Pemvidutide, that shows promising results in targeting fat mass and promoting weight loss. The obesity treatment market is expected to grow exponentially, reaching $77 billion by 2030, creating a significant opportunity for Altimmune. Altimmune needs to find a partnership to compete with established players like Novo Nordisk and Eli Lilly, but the potential of Pemvidutide is high, making it a buy. Read the full article on Seeking Alpha

Seeking Alpha • Apr 12

Buy Altimmune's Potential Market Disruption With Pemvidutide

Summary Altimmune is a clinical-stage biopharmaceutical company focused on developing peptide-based treatments for obesity and liver diseases. Their lead drug candidate, Pemvidutide, targets glucagon-like peptide-1 and glucagon receptors to produce weight loss with reduced side effects. Pemvidutide has shown promising results in clinical trials for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH), and the company is seeking partnerships for further development. ALT's strategic shift includes partnering discussions to enhance Pemvidutide's development pathway and potential commercialization. Overall I think ALT is a viable investment for investors who are aware of the inherent risks in biotech. Read the full article on Seeking Alpha

Seeking Alpha • Mar 27

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Summary Positive results achieved from phase 2 MOMENTUM study, whereby patients not only achieved significant weight loss over a 48-week period with pemvidutide but also had lean mass preservation. It is said that the GLP-1 market could exceed $100 billion by 2030. Results from the phase 2b IMPACT study, using pemvidutide for the treatment of patients with MASH, expected to be released Q1 of 2025. Altimmune had $198 million in cash as of December 31st of 2023; It will likely have to continue to tap into the ATM agreement or find another way to raise cash to fund its pipeline. Read the full article on Seeking Alpha

Seeking Alpha • Feb 27

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Summary Altimmune's stock price has experienced extreme volatility, but jumped by >20% yesterday due to the potential of pemvidutide, a drug candidate for obesity and liver disease. Some analysts believe pemvidutide can have a similar impact as Eli Lilly's tirzepatide and Novo Nordisk's semaglutide on these two indications - both Pharma's share prices have been soaring. Altimmune's previous COVID and anthrax vaccine efforts were unsuccessful, but there is optimism - based on some promising data - that pemvidutide could be different and provide a valuable opportunity. Ultimately, however, with its drug having some problematic side effects and the company struggling for funding, I'm giving Altimmune the thumbs down. There is a data readout in relation to a Hepatitis B therapy due this quarter - a small hedge against pemvidutide struggles - many will disagree, but selling after the recent bull run may be the right option. Read the full article on Seeking Alpha

Seeking Alpha • Feb 12

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Summary Altimmune's stock surged after revealing promising obesity treatment data for pemvidutide, a GLP-1/glucagon agonist, despite existing competition. Pemvidutide demonstrated dose-dependent weight loss in Phase 2, but high adverse event rates, especially gastrointestinal, led to notable discontinuation. Financially, Altimmune holds a strong current ratio with a 21-month runway despite the need for future capital to sustain operations. Investment Recommendation: Hold ALT stock due to the balance between pemvidutide's potential and its competition, tolerability concerns, and financial health. Read the full article on Seeking Alpha

Analyse-artikel • Feb 10

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Seeking Alpha • Jan 10

Thoroughly Derisked, Altimmune Is Now A Great Buy

Summary Altimmune's weight loss drug, Pemvidutide, showed promising results in a phase 2 trial, with a mean weight loss of 15.6% at week 48. The drug also demonstrated better CV risk reduction, lipid changes and tolerability than its competitors, semaglutide and tirzepatide. Altimmune's stock is undervalued compared to the potential market success of a weight loss drug, with potential for significant upside. Read the full article on Seeking Alpha

Analyse-artikel • Oct 11

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analyse-artikel • Jun 27

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyse-artikel • Feb 12

Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Rendement voor aandeelhouders

	ALT	US Biotechs	US Markt
7D	16.9%	3.7%	3.2%
1Y	-47.6%	41.9%	31.0%

Rendement versus industrie: ALT presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 41.9 % opleverde.

Rendement versus markt: ALT presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31 % opleverde.

Prijsvolatiliteit

Is ALT's price volatile compared to industry and market?
ALT volatility
ALT Average Weekly Movement	10.4%
Biotechs Industry Average Movement	10.6%
Market Average Movement	7.1%
10% most volatile stocks in US Market	16.1%
10% least volatile stocks in US Market	3.2%

Stabiele aandelenkoers: ALT heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 10% ) van ALT is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1997	57	Jerry Durso	altimmune.com

Altimmune, Inc., een biofarmaceutisch bedrijf in een laat klinisch stadium, richt zich op de ontwikkeling van nieuwe therapieën voor ernstige leverziekten. De belangrijkste productkandidaat is pemvidutide, een GLP-1/glucagon dubbele receptoragonist, die zich in Fase 3 van het klinisch onderzoek bevindt voor de behandeling van metabole disfunctie-geassocieerde steatohepatitis, alcoholmisbruikstoornis en alcoholgeassocieerde leverziekte. Het bedrijf werd opgericht in 1997 en heeft zijn hoofdkantoor in Gaithersburg, Maryland.

Altimmune, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Altimmune zich tot de beurswaarde?
ALT fundamentele statistieken
Marktkapitalisatie	US$633.09m
Inkomsten(TTM)	-US$88.09m
Inkomsten(TTM)	US$41.00k

Over9,999x

P/S-verhouding

-6.7x

Koers/Winstverhouding

Is ALT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ALT resultatenrekening (TTM)
Inkomsten	US$41.00k
Kosten van inkomsten	US$66.43m
Brutowinst	-US$66.39m
Overige uitgaven	US$21.70m
Inkomsten	-US$88.09m

Laatst gerapporteerde inkomsten

Dec 31, 2025

Volgende inkomensdatum

May 13, 2026

Winst per aandeel (EPS)	-0.45
Brutomarge	-161,929.27%
Nettowinstmarge	-214,860.98%
Schuld/Eigen Vermogen Verhouding	15.2%

Hoe presteerde ALT op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/05/07 01:42
Aandelenkoers aan het einde van de dag	2026/05/07 00:00
Inkomsten	2025/12/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Altimmune, Inc. wordt gevolgd door 19 analisten. 10 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Eliana Merle	Barclays
William Wood	B. Riley Securities, Inc.
Mayank Mamtani	B. Riley Securities, Inc.

Altimmune (ALT) Aandelenoverzicht

Beloningen

Risicoanalyse

Altimmune, Inc. Concurrenten

Tectonic Therapeutic

Crescent Biopharma

Prothena

Zura Bio

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Altimmune, Inc. to Report Q1, 2026 Results on May 13, 2026

Altimmune, Inc. has completed a Follow-on Equity Offering in the amount of $224.98925 million.

Altimmune, Inc. has filed a Follow-on Equity Offering.

Altimmune: Considering If A Repeat Of The 2025 Run-Up Is On Tap

Altimmune, Inc. to Report Q4, 2025 Results on Mar 05, 2026

Altimmune, Inc., Annual General Meeting, Apr 16, 2026

Recent updates

Altimmune, Inc. to Report Q1, 2026 Results on May 13, 2026

Altimmune, Inc. has completed a Follow-on Equity Offering in the amount of $224.98925 million.

Altimmune, Inc. has filed a Follow-on Equity Offering.

Altimmune: Considering If A Repeat Of The 2025 Run-Up Is On Tap

Altimmune, Inc. to Report Q4, 2025 Results on Mar 05, 2026

Altimmune, Inc., Annual General Meeting, Apr 16, 2026

Altimmune, Inc. has completed a Follow-on Equity Offering in the amount of $74.99535 million.

Altimmune, Inc. has filed a Follow-on Equity Offering in the amount of $74.99535 million.

Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Altimmune, Inc. Announces Positive Topline Results from the Impact Phase 2B Mash Trial

Altimmune, Inc. Announces CEO Changes

Altimmune, Inc. Announces Publication of Impact Phase 2B Trial Data in the Lancet and Concurrent Late-Breaking Oral Presentation At Aasld the Liver Meeting®? 2025

Altimmune, Inc. Presents Ai-Based Analysis of Liver Fibrosis Reduction from Impact Phase 2B Trial of Pemvidutide Inash in Late-Breaking Poster At Aasld the Liver Meeting®? 2025

Altimmune, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Altimmune, Inc. Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Altimmune, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Altimmune, Inc. Announces the Appointment of Christophe Arbet-Engels as Chief Medical Officer, Effective October 1, 2025

Altimmune, Inc. Appoints Linda M. Richardson to the Role of Chief Commercial Officer, Effective September 16, 2025

Altimmune, Inc. Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Altimmune, Inc., Annual General Meeting, Sep 25, 2025

Holzer & Holzer, Llc Files Shareholder Class Action Lawsuit Against Altimmune, Inc

Altimmune Appoints Jerry Durso as Chairman, Effective August 12, 2025

Levi & Korsinsky, LLP Announces Filing of Class Action Against Altimmune, Inc

Altimmune, Inc. to Report Q2, 2025 Results on Aug 12, 2025

Altimmune, Inc. Announces Initiation of Restore Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease

Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000E Value Index

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

Altimmune, Inc. Announces Initiation of RECLAIM Phase 2 Trial Evaluating Efficacy and Safety of Pemvidutide in Alcohol Use Disorder

Altimmune, Inc. announced that it expects to receive $100 million in funding from Hercules Capital, Inc.

Altimmune, Inc. to Report Q1, 2025 Results on May 13, 2025

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine

Altimmune, Inc. Announces Retirement of Scott Harris as Chief Medical Officer, Effective February 28, 2026

Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2

Altimmune, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Altimmune, Inc. Announces Board Appointments

Altimmune, Inc. to Report Q4, 2024 Results on Feb 27, 2025

Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH

Is Altimmune (NASDAQ:ALT) In A Good Position To Invest In Growth?

Altimmune Could Find A Partner For Its Phase 3 Exercise

Altimmune 2025: Redefining Obesity And MASH Treatment

Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024

Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health

Altimmune, Inc. Appoints Greg Weaver as Chief Financial Officer

Altimmune, Inc. Announces Successful Completion of End-of-Phase 2 Meeting with FDS for Pemvidutide in the Treatment of Obesity

Altimmune, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Regulatory And Clinical Catalysts Ahead For Altimmune

Consider Buying Potential Takeover Target Altimmune

Altimmune, Inc. Completes Enrollment in Phase 2B Impact Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (Mash)

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Altimmune, Inc., Annual General Meeting, Sep 26, 2024

Altimmune, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Altimmune, Inc. Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology

Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association’s 84th Scientific Sessions

Altimmune, Inc. Presents Data at EASL International Liver Congress™? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)

Pomerantz LLP Announces Filing of Class Action Against Altimmune, Inc. and Certain Officers

Altimmune, Inc. to Report Q1, 2024 Results on May 09, 2024